Fluvoxamine Maleate in the Treatment of OCD: A Post-marketing Clinical Study in Children and Adolescents
Researchers are comparing Fluvoxamine maleate and placebo to find out how the approaches affect obsessive thoughts and compulsive behaviours in children and adolescents with OCD.
Understand this study
What is this study about?
Researchers are comparing Fluvoxamine maleate and placebo to find out how the approaches affect obsessive thoughts and compulsive behaviours in children and adolescents with OCD.
Who could participate?
This study is for people with OCD. Listed age limits: 8 years to 18 years. Other eligibility criteria apply.
- Listed locations
- Chiba Prefecture and 10 more locationsSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
What to know before participating
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
- Recruitment status
- Terminated
- Enrollment listed in the registry
- 20
- Sponsor
- Solvay Pharmaceuticals
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- Japan
- Age range
- From 8 Years to 18 Years
- Official registry ID
- NCT00352768
- Official title
Show the full official title
SME3110 (Fluvoxamine Maleate) in the Treatment of Obsessive-Compulsive Disorder: A Post-marketing Clinical Study in Children and Adolescents (8 Through 18 Years of Age) -A Double-blind, Randomized, Placebo-controlled Study
Recruitment & locations
Chiba Prefecture · Fukuoka Prefecture · Hiroshima Prefecture
7 more locations
- Hokkaido Prefecture
- Hyogo Prefecture
- Kagawa Prefecture
- Kumamoto Prefecture
- Mie Prefecuture
- Nara Prefecture
- Tokushima Prefecture
Interested in joining this study?
Questions about this study
What is this study about?
Researchers are comparing Fluvoxamine maleate and placebo to find out how the approaches affect obsessive thoughts and compulsive behaviours in children and adolescents with OCD.
Who is behind this study?
The study sponsor is Solvay Pharmaceuticals.
Does this study involve medication?
Yes. The study involves medication, including Fluvoxamine maleate and Placebo.
Who can participate?
This study is for people with OCD. Listed age limits: 8 years to 18 years. Other eligibility criteria apply.
Is this study still recruiting?
The registry lists this study as terminated.
